One potential strategy for future drug development could be to combine farnesyltranferase enzyme inhibitors with STAT3 targeted therapies in IBC and there also seems to be interaction between these two pathways in non-IBC [101]. Here, STAT3 is linked to inflammatory breast carcinoma.